BioSpace News Archive

InDex Pharmaceuticals Holding AB announced that the company has received positive feedback from the Japanese regulatory authority, the Pharmaceuticals and Medical Devices Agency, regarding the clinical development plan for a future marketing authorization application for the company’s TLR9 agonist cobitolimod, for the treatment of moderate to severe left-sided ulcerative colitis.

EVONETIX LTD, the synthetic biology company bringing semiconductor technology to DNA synthesis, announced the opening of its early access program for semiconductor synthesised DNA.

RIVANNA®, developers of world-first, imaging-based medical solutions, announced the results of a clinical case study demonstrating that Accuro played a crucial role in aiding the placement of an epidural catheter in a parturient with extreme obesity.

CURE Pharmaceutical Holding Corp., a proprietary platform technology company, announced the appointment of former CEO Rob Davidson to Chairman of the Board of Directors.

Amphastar Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has approved the Company’s New Drug Application for Epinephrine injection USP, 1 mg/10mL Single Dose Pre-Filled Syringe.

Wilmington, Delaware, United States, Transparency Market Research Inc. – The demand in the global bioimpendance analysers market is surging owing to high growth potential amongst emerging economies such as Brazil and India.

Wilmington, Delaware, United States, Transparency Market Research Inc. – In the last few years, the manufacturers have created novel aesthetic gadgets, resulting in a rise in demand for aesthetic treatments.

J INTS BIO announced that the pre-clinical data of its novel, orally administered 4th generation EGFR TKI ‘JIN-A02' was presented on the 8th of August, at the 2022 IASLC World Conference on Lung Cancer held in Vienna, Austria, during the official session entitled “Overcoming Resistance to EGFR Inhibitors”.

Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced that the Company has developed a Peptide Docking Vehicle to achieve a peptide-enhanced GalNAc platform for siRNA drug delivery.

AlzeCure Pharma AB announced that Drug Discovery Today has published a new review article on the biological mechanism underlying AlzeCure’s NeuroRestore platform and its leading drug candidate ACD856.